Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created post of chief people and communications officer.
Mr. Worsley has over 25 years of biotechnology experience and will oversee business development and corporate strategy. He most recently served as senior vice president of business development at IndiMolecular, Inc.
Mr. Worsley also was vice president of business development at Peregrine Pharmaceuticals, Inc., where he secured research and clinical agreements with the Memorial Sloan Kettering Cancer Center and with Astra Zeneca and oversaw worldwide licensing. He also held senior positions at Centrose Pharmaceuticals, Inc., Intrexon Corp., and Zosano Pharmaceuticals, Inc.
Mr. Worsley earned an M.B.A. in finance from the University of Washington and a B.S. in international economics and finance from the University of Utah.
Ms. Fitzpatrick joined Sutro in 2008 and, over the past ten years, has been a senior advisor and an integral part of the senior management team working toward creating a collaborative, world-class company. Her ongoing focus will be to guide the human capital and corporate communications strategy.
Ms. Fitzpatrick has extensive experience overseeing human resources and corporate communications for publicly-held companies. Before joining Sutro, she served as vice president of human resources and corporate communications for Gilead Sciences, Inc., and as director of investor relations and director of compensation, benefits and systems for Genentech, Inc. She graduated with honors from San Francisco State University with a degree in psychology and sociology.
About Sutro Biopharma
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Sutro’s proprietary and integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF™, led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed antibody drug conjugates, or ADCs. STRO-001 is a potentially first-in-class ADC targeting CD-74, a protein highly expressed in multiple myeloma and Non Hodgkin’s Lymphoma, and is currently in Phase I studies. STRO-002 is a potentially best-in-class ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Sutro plans to file an investigational new drug application for STRO-002 in the fourth quarter of 2018.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
To date, Sutro has designed cytokine-based immuno-oncology therapies, antibody-drug conjugates, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Sutro’s platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.
In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
# # #
(917) 217-1838 mobile